The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma
Jean-Noël Hubert1, Voreak Suybeng2, Maxime Vallée1
1Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 69372 Lyon, France.
Abstract:
Background: Malignant melanoma and RCC have different embryonic origins, no common lifestyle risk factors but intriguingly share biological properties such as immune regulation and radioresistance. An excess risk of malignant melanoma is observed in RCC patients and vice versa. This bidirectional association is poorly understood, and hypothetic genetic co-susceptibility remains largely unexplored. Results: We hereby provide a clinical and genetic description of a series of 125 cases affected by both malignant melanoma and RCC. Clinical germline mutation testing identified a pathogenic variant in a melanoma and/or RCC predisposing gene in 17/125 cases (13.6%). This included mutually exclusive variants in MITF (p.E318K locus, N = 9 cases), BAP1 (N = 3), CDKN2A (N = 2), FLCN (N = 2), and PTEN (N = 1). A subset of 46 early-onset cases, without underlying germline variation, was whole-exome sequenced. In this series, thirteen genes were significantly enriched in mostly exclusive rare variants predicted to be deleterious, compared to 19,751 controls of similar ancestry. The observed variation mainly consisted of novel or low-frequency variants (<0.01%) within genes displaying strong evolutionary mutational constraints along the PI3K/mTOR pathway, including PIK3CD, NFRKB, EP300, MTOR, and related epigenetic modifier SETD2. The screening of independently processed germline exomes from The Cancer Genome Atlas confirmed an association with melanoma and RCC but not with cancers of established differing etiology such as lung cancers. Conclusions: Our study highlights that an exome-wide case-control enrichment approach may better characterize the rare variant-based missing heritability of multiple primary cancers. In our series, the co-occurrence of malignant melanoma and RCC was associated with germline variation in the PI3K/mTOR signaling cascade, with potential relevance for early diagnostic and clinical management.
Insights
This study reveals a genetic link between malignant melanoma and renal cell carcinoma (RCC), identifying shared rare variants in the PI3K/mTOR pathway. These findings suggest a potential genetic co-susceptibility for these cancers.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Malignant melanoma and renal cell carcinoma (RCC) share biological properties like immune regulation and radioresistance, despite different origins.
- An increased risk of one cancer is observed in patients with the other, suggesting a potential shared genetic basis.
- Previous research has not fully explored the genetic co-susceptibility between malignant melanoma and RCC.
Purpose of the Study:
- To clinically and genetically characterize patients with both malignant melanoma and RCC.
- To identify germline genetic variants predisposing to both cancers.
- To explore the role of rare variants in the PI3K/mTOR pathway in the co-occurrence of these cancers.
Main Methods:
- Clinical and germline mutation testing in 125 patients with both malignant melanoma and RCC.
- Whole-exome sequencing of 46 early-onset cases without identified germline variants.
- Comparison of rare variants in 13 genes against 19,751 controls from The Cancer Genome Atlas (TCGA).
Main Results:
- Pathogenic variants in known cancer predisposition genes (MITF, BAP1, CDKN2A, FLCN, PTEN) were found in 13.6% of cases.
- Significant enrichment of rare, predicted deleterious variants in PI3K/mTOR pathway genes (PIK3CD, MTOR, etc.) and epigenetic modifiers (SETD2) in early-onset cases.
- Association of germline variants with both melanoma and RCC confirmed in TCGA data, but not with lung cancer.
Conclusions:
- Exome-wide case-control enrichment analysis can identify rare variants contributing to multiple primary cancers.
- The co-occurrence of malignant melanoma and RCC is associated with germline variation in the PI3K/mTOR signaling pathway.
- These findings have implications for early diagnosis and clinical management of patients with both cancers.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
MAPK Signaling Cascades


